相关实验视频
Updated: May 10, 2025
10:43
Evaluating In Vitro DNA Damage Using Comet Assay
Published on: October 11, 2017
37.0K
对Olaparib与Niraparib的安全性概况进行比较研究:分析EudraVigilance的现实数据
Desirèe Speranza1, Fausto Omero2, Vincenzo Cianci3
1Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98166 Messina, Italy.
Pharmaceuticals (Basel, Switzerland)
|April 26, 2025
概括
用于卵巢癌的olaparib和niraparib显示出不同的现实世界的安全性. 与olaparib相比,niraparib具有更高的严重不良事件风险,需要个性化患者管理.
科学领域:
- 药物监督 药物监督 药物监督
- 在瘤学瘤学.
- 药品安全 药品安全
背景情况:
- 奥拉巴里布和尼拉巴里布是PARP抑制剂,在卵巢癌治疗中至关重要.
- 这些药物的真实安全数据需要在临床试验之外进一步阐明.
研究的目的:
- 使用EudraVigilance数据,描述olaparib和niraparib的不良药物反应 (ADR).
- 将olaparib和niraparib之间的ADRs的频率和性质进行比较.
- 与现有的临床试验数据对比营销后的安全性调查结果.
主要方法:
- 追溯分析EudraVigilance从2017年至2024年的个案安全报告 (ICSR).
- 使用描述性统计和不成比例分析进行ADR比较.
- 专注于Olaparib和Niraparib在现实环境中的安全数据.
主要成果:
- 这两种药物的常见副作用包括恶心,贫血和疲劳.
- 奥拉巴里布显示,肌肉发育不良综合征,AML和间歇性肺部疾病的风险更高.
- 尼拉巴里表现出胃肠道事件的增加,血小板缩,以及更高的严重副作用率.
结论:
- 在olaparib和niraparib的安全性概况中存在显著的差异.
- 现实世界的数据显示,与试验相比,尼拉帕里布的使用频率更高的外围神经病变等ADR.
- 个性化监测和管理对于优化这些PARP抑制剂患者的治疗结果至关重要.
相关概念视频
01:20Comparing the Survival Analysis of Two or More Groups
85
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
85
01:12Hazard Ratio
67
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
For example, in a clinical trial...
67
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
106
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
106
01:21Cancer Survival Analysis
298
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
298
01:24Kaplan-Meier Approach
55
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
55